Healthcare & Life Sciences
Okairos AG
Switzerland
series-b
series-b
Stage
1
Investors
About
Okairos AG was a biotechnology company developing viral-vectored vaccines using adenoviral and modified vaccinia Ankara (MVA) platforms to induce strong T-cell responses for infectious diseases and immunotherapy.
Explore Okairos AG's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.